1. GPCR/G Protein
  2. EBI2/GPR183


The Epstein-Barr virus (EBV) induced receptor 2 (EBI2; also known as GPR183) is an orphan member of the 7TM receptor family A. EBI2 is a constitutively active seven-transmembrane receptor. EBI2 has been placed in varying 7TM receptor subgroups by different phylogenetic analyses as being a target of peptide or lipid ligands. EBI2 constitutively activates extracellular signal-regulated kinase (ERK) in a pertussis toxin-insensitive manner. EBI2 is up-regulated up to 200-fold in B cells following EBV infection.

EBI2 activation stimulates immune cell migration and has been genetically linked to autoimmune diseases including type 1 diabetes. Small molecule modulators of EBI2 can be useful for probing the function of the receptor and its relevance to human diseases.

EBI2/GPR183 Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-116814
    ML401 Antagonist 99.93%
    ML401, a potent chemical probe, selectively antagonizes EBI2 (also known as GPR183) with an IC50 of 1.03 nM. ML401 displays activity in a chemotaxis assay (IC50=6.24 nM). ML401 shows good stability and no toxicity[1].
  • HY-113962
    7α,25-Dihydroxycholesterol Agonist
    7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells[1][2].
  • HY-12336
    NIBR189 Inhibitor 99.41%
    NIBR189 is an EBI2 (Epstein-Barr virus-induced gene 2) antagonist. NIBR189 inhibits human and mouse EBI2 with IC50s of 11 and 16 nM, respectively. NIBR189 can be used for the research of autoimmune diseases[1].
  • HY-101192
    GSK682753A Inhibitor
    GSK682753A is a selective and highly potent inverse agonist of the epstein-barr virus-induced receptor 2 (EBI2) with an IC50 of 53.6 nM.
  • HY-147222
    SAE-14 Antagonist 98.26%
    SAE-14 (compound SAE-14) is a potent, specific GPR183 antagonist with an IC50 value of 28.5 nM, can antagonize 7α, 25-OHC–induced calcium mobilization with IC50 value below 50 nM in HL-60 cells. GPR183 antagonist-1 can reverse allodynia in mice[1].
  • HY-400897
    7α,25-Dihydroxycholesterol intermediate-1
    7α,25-Dihydroxycholesterol intermediate-1 is an intermediate in the synthesis of 7α,25-Dihydroxycholesterol (HY-113962). 7α,25-Dihydroxycholesterol (7α,25-OHC) can be used as a ligand to target the orphan GPCR receptor EBI2 (GPR183). body, used to synthesize the corresponding PROTEACs[1].
  • HY-162011
    GPR183 antagonist-2 Antagonist 99.96%
    GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases[1].
  • HY-157939
    GPR183 antagonist-3 Antagonist
    GPR183 antagonist-3 (compound 33) is an oral active GPR183 antagonist with the IC50 of 8.7 μM. GPR183 antagonist-3 displays strong in vitro antimigration and anti-inflammatory activity in monocytes, and improves the pathological symptoms of DSS-induced experimental colitis[1].
  • HY-113962S
    7α,25-Dihydroxycholesterol-d6 is deuterium labeled 7α,25-Dihydroxycholesterol. 7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly